trending Market Intelligence /marketintelligence/en/news-insights/trending/oju85okerax8cy6nfd38bq2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Heron Therapeutics stocks rise on positive late-stage trial results

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Heron Therapeutics stocks rise on positive late-stage trial results

Heron Therapeutics Inc. said its treatment HTX-011 was better at reducing post-surgery pain when compared to the current standard-of-care local anesthetic.

HTX-011 was being evaluated against bupivacaine — an anesthetic sold under multiple brand names, including Marcaine — in two separate phase 3 trials known as study 301/Epoch1 and study 302/Epoch2.

The drug was also evaluated against a placebo.

Study 301, which involved 412 patients who had undergone a bunionectomy surgery, resulted in a 27% reduction in pain intensity when comparing HTX-011 to placebo and an 18% reduction when compared to bupivacaine.

Over 72 hours after surgery, patients receiving HTX-011 consumed 37% fewer opioids than placebo and 25% fewer opioids than patients receiving bupivacaine.

Meanwhile, 29% of patients receiving HTX-011 required no opioid medication for 72 hours post-surgery, compared to only 2% receiving placebo and 11% receiving bupivacaine.

Study 302, which enrolled 418 subjects who had undergone a hernia repair surgery, resulted in a 23% reduction in the intensity of pain when compared to placebo and a 21% reduction in pain when compared to bupivacaine.

Over 72 hours after surgery, patients receiving HTX-011 consumed 38% fewer opioids than placebo patients and 25% fewer opioids than patients receiving bupivacaine.

Furthermore, 51% of patients receiving HTX-011 required no opioid medication for 72 hours post-surgery compared to only 22% receiving placebo and 40% receiving bupivacaine.

The San Diego-based company's stock was up 26.26% on the news to $27.15 per share as of 11:44 a.m. ET on March 19.